Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > If it’s just $$ we need, then let’s go merge with one of the

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Nov 17, 2021 4:21pm

213 Views

Post# 34137982

RE:If it’s just $$ we need, then let’s go merge with one of the

Wait for TH1902 to get through Phase 1. You'll know a whole lot more about the future revenue potential of the company by then. Further, doing that is the equivalent of selling shares at this price or less. No one want's that when milestones are close by and so far the science looks supportive.